This 48-page reference document compiles the presentations and recommendations from the world's leading centers, including :
QST (Japan), CNAO (Italy), HIT(Germany), MedAustron (Austria), Mayo Clinic (USA) and many others.
From Japan to the United States, by way of Germany, Italy, and France, more than 120 international experts gathered at the University of Caen for the "Hadrontherapy for Life" symposium.
Organized by CYCLHAD, the University of Caen Normandy, the François Baclesse Center, and the Normandy Region - with support from Normandy Hadrontherapy and IBA - this event marks a major milestone in the arrival of multi-ion hadrontherapy in France.
Over the course of two days, researchers, clinicans, and engineers presented the latest advances in heavy particle radiotherapy, a discipline that combines physical precision and biological selectivity through the use of protons, carbon-ions, and helium ions.
Emerging clinical indications : pancreatic cancers, pediatric tumors, and radioresistant relapses.
Advances in radiobiology : molecular interactions, immunotherapy and the unique biological effects of heavy ions.
Technological innovations : multi-ion treatment planning, upright therapy, and AI applications in dosimetry.
Medico-economic and training challenges : Towards an integrated and sustainable European industry.
This symposium also paved the way for PTCOG 2026, the world's largest particle therapy congress, which will be held in France, in Deauville-Caen, from June 8 to 13, 2026 : https://ptcog64.org/
With the upcoming commissioning of the C400 IONS and the arrival of multi-particle beams (protons, carbon, and helium), CYCLHAD and its partners establishing themselves as key players in precision medicine and transnational research on a international scale.
